[1]
|
Ross, R. (1999) Atherosclerosis—An inflammatory disease. The New England Journal of Medicine, 340, 115- 126. doi:10.1056/NEJM199901143400207
|
[2]
|
Libby, P., Ridker, P.M., and Maseri, A. (2002) Inflammation and atherosclerosis. Circulation, 105, 1135-1143.
doi:10.1161/hc0902.104353
|
[3]
|
Liuzzo, G., Biasucci, L.M., Gallimore, R., et al. (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. The New England Journal of Medicine, 331, 417-424.
doi:10.1056/NEJM199408183310701
|
[4]
|
Biasucci, L.M., Liuzzo, G., Grillo, R.L., et al. (1999) Elevated levels of C-reactive protein at discharge in patients with unstable angina predicts recurrent instability. Circulation, 99, 855-860. doi:10.1161/01.CIR.99.7.855
|
[5]
|
Liuzzo, G., Buffon, A., Biasucci, L.M., et al. (1998) Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation, 98, 2370- 2376. doi:10.1161/01.CIR.98.22.2370
|
[6]
|
Levi, M., van der Poll, T. and Büller, H.R. (2004) Bidirectional relation between inflammation and coagulation. Circulation, 109, 2698-2704.
doi:10.1161/01.CIR.0000131660.51520.9A
|
[7]
|
Furman, M.I., Krueger, L.A., Linden, M.D., Barnard, M.R., Frelinger III, A.R. and Michelson, A.D. (2004) Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. Journal of the American College of Cardiology, 43, 2319-2325.
doi:10.1016/j.jacc.2003.12.055
|
[8]
|
Aukrust, P., Damas, J.K. and Solum, N.O. (2004) Soluble CD40L and platelets: Self-perpetuating pathogenic loop in thrombosis and inflammation. Journal of the American College of Cardiology, 43, 2326-2328.
doi:10.1016/j.jacc.2004.03.023
|
[9]
|
Aukrust, P., Müller, F., Ueland, T., et al. (1999) Enhanced levels of soluble and membrane bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation, 100, 614-620. doi:10.1161/01.CIR.100.6.614
|
[10]
|
Henn, V., Steinbach, S., Büchner, K., Presek, P. and Kroc- zek, R. (2001) The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood, 98, 1047- 1054. doi:10.1182/blood.V98.4.1047
|
[11]
|
Henn, V., Slupsky, J.R. and Grafe, M. (1998) CD40 lig- and in activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 391, 591-594.
doi:10.1038/35393
|
[12]
|
Ambrose, J.A., Winters, S.L., Arora, R.R., et al. (1985) Coronary angiographic morphology in myocardial infarction: A link between the pathogenesis of unstable angina and myocardial infarction. Journal of the American College of Cardiology, 6, 1233-1238.
doi:10.1016/S0735-1097(85)80207-2
|
[13]
|
Ambrose, J.A., Hjemdahl-Monsen, C.E., Borrico, S., Gor- lin, R. and Fuster, V. (1988) Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave myocardial infarction. Journal of the American College of Cardiology, 61, 244-247.
doi:10.1016/0002-9149(88)90924-1
|
[14]
|
Cohen, M., Merino, A., Hawkins, L., Greenberg, S. and Fuster, V. (1991) Clinical and angiographic characteristics and outcome of patients with restunstable angina occurring during regular aspirin use. Journal of the American College of Cardiology, 18, 1458-1462.
doi:10.1016/0735-1097(91)90675-Y
|
[15]
|
Myers, G.L., Rifai, N., Tracy, R.P., et al. (2004) CDC; AHA. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Report from the laboratory science discussion group. Circulation, 110, 545-549.
doi:10.1161/01.CIR.0000148980.87579.5E
|
[16]
|
Bereczki, C., Nagy, E., Pal, A., Magyar, M.T. and Balla, J. (2003) Should soluble CD40 ligand be measured from serum or plasma samples? Letter. Arteriosclerosis, Throm-bosis, and Vascular Biology, 23, 1129-1131.
doi:10.1161/01.ATV.0000072368.37740.8E
|
[17]
|
Ahn, E.R., Lander, G., Jy, W., Bidot, C.J., Jimenez, J.J., Horstman, L.L. and Ahn, Y.S. (2004) Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk. Thrombosis Research, 114, 143-148.
doi:10.1016/j.thromres.2004.06.005
|
[18]
|
Calvo, J., Martínez, N., Etxagibel, A., et al. (2002) Allelic frequencies of polymorphic variants of cytokine genes (IL-1A, IL-1B, IL-1RN, IL-6, IL-10, IL-12P40, and IFNG ) in a Spanish population. Inmunología, 21, 76-86.
|
[19]
|
Lincoff, A.M., Kereiakes, D.J., Mascelli, M.A., et al. (2001) Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation, 104, 163-167.
doi:10.1161/01.CIR.104.2.163
|
[20]
|
Merino, A., Gayá, A., Segura, I., et al. (2004) Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: Effect of the ?174 G/C IL-6 gene polymorphism. Journal of the American College of Cardiology, 94, 1300-1303.
doi:10.1016/j.amjcard.2004.07.119
|
[21]
|
Merino, A., Artaiz, M., Bergadá, J., Riera, M., Vidal, B. and Rodriguez, A. (2002) El eptifibatide reduce los valores de Proteina C Reactiva tras angioplastia coronaria. Revista Espa?ola de Cardiología, 55, 186-189.
|
[22]
|
James, S.K., Siegbahn, A., Armstrong, P.A., et al. (2004) Activation of the inflammation, coagulation and fibrin-olysis Systems, without influence of abciximab infusión in patients with non-ST-elevation acute coronary síndromes treated with dalteparin: A GUSTO IV substudy. American Heart Journal, 147, 267-274.
doi:10.1016/j.ahj.2003.09.014
|
[23]
|
Gawaz, M., Langer, H. and May, A.E. (2005) Platelets in inflammation and atherogenesis. The Journal of Clinical Investigation, 115, 3378-3384. doi:10.1172/JCI27196
|
[24]
|
Silber, S., Albertsson, P., Aviles, F.F., et al. (2005) Guidelines for percutaneous coronary interventions.The task force for percutaneous coronary interventions of the European Society of Cardiology. European Heart Journal, 26, 804-847. doi:10.1093/eurheartj/ehi138
|
[25]
|
Palmerini, T., Nedelman, M.A., Scudder, L.E., et al. (2002) Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates. Journal of the American College of Cardiology, 40, 360- 366. doi:10.1016/S0735-1097(02)01951-4
|
[26]
|
Curran, M.P. and Keating, G.M. (2005) Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs, 65, 2009-2035.
doi:10.2165/00003495-200565140-00007
|
[27]
|
Anand, S.X., Viles-Gonzalez, J.S., Badimon, J.J., Cavusoglu, E. and Marmur, J.D. (2003) Membrane-associated CD40L and sCD40L in atherothrombotic disease. Journal of Thrombosis and Haemostasis, 90, 377-384.
|
[28]
|
Aukrust, P., W?hre, T., Damas, J.K., Gullestad, L. and Solum, N.O. (2001) Inflammatory role of platelets in acute coronary syndromes. Heart, 86, 605-606.
doi:10.1136/heart.86.6.605
|
[29]
|
Antoniades, C., Bakogiannis, C., Tousoulis, D., Antono-poulos, A.S. and Stefanadis, C. (2009) The CD40/CD40 ligand system. Journal of the American College of Cardiology, 54, 669-677. doi:10.1016/j.jacc.2009.03.076
|
[30]
|
Libby, P. and Simon, D.I. (2001) Inflammation and Thrombosis: The Clot Thickens. Circulation, 103, 1718-1720.
doi:10.1161/01.CIR.103.13.1718
|
[31]
|
Libby, P., Ridker, P.M. and Hansson, G. (2009) Inflammation in atherosclerosis: From pathophysiology to practice. Journal of the American College of Cardiology, 54, 2129-2138. doi:10.1016/j.jacc.2009.09.009
|
[32]
|
Muhlestein, J.B. (2010) Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Jour- nal of Thrombosis and Haemostasis, 103, 71-82.
doi:10.1160/TH09-03-0177
|